Navigating Neurotoxicity in CAR-T Therapy

This chapter examines the neurotoxic effects linked to siltacel in CAR-T therapy, emphasizing the delayed onset of symptoms and managing challenges. It also discusses the significance of patient education about potential life-altering complications and the role of bridging therapies in improving outcomes. Furthermore, the chapter highlights advancements in CAR-T therapies for multiple myeloma, comparing different treatment types and exploring emerging therapies aimed at mitigating side effects.